Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:AURA NASDAQ:CRDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$19.74+5.6%$20.03$16.65▼$31.26$870.39M0.91765,642 shs748,242 shsAURAAura Biosciences$6.63-2.5%$7.24$4.73▼$9.53$685.45M0.39436,322 shs347,125 shsCRDLCardiol Therapeutics$1.11-3.5%$1.33$0.88▼$1.71$127.92M0.72374,893 shs427,263 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%+4.72%-17.85%+2.07%-23.67%AURAAura Biosciences0.00%-11.24%-19.15%+18.39%+7.98%CRDLCardiol Therapeutics0.00%-9.02%-14.62%+14.34%-23.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$19.74+5.6%$20.03$16.65▼$31.26$870.39M0.91765,642 shs748,242 shsAURAAura Biosciences$6.63-2.5%$7.24$4.73▼$9.53$685.45M0.39436,322 shs347,125 shsCRDLCardiol Therapeutics$1.11-3.5%$1.33$0.88▼$1.71$127.92M0.72374,893 shs427,263 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%+4.72%-17.85%+2.07%-23.67%AURAAura Biosciences0.00%-11.24%-19.15%+18.39%+7.98%CRDLCardiol Therapeutics0.00%-9.02%-14.62%+14.34%-23.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.88Reduce$24.0021.58% UpsideAURAAura Biosciences 2.25Hold$20.50209.20% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50665.77% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, ORPH, AMPH, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$23.00 ➝ $20.005/14/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$30.00 ➝ $19.005/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026AURAAura Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.005/11/2026AMPHAmphastar Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$25.00 ➝ $21.005/8/2026AMPHAmphastar Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/29/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $24.004/21/2026AMPHAmphastar Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$30.00 ➝ $22.004/10/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/8/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$30.00 ➝ $23.004/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.21$4.25 per share4.64$17.17 per share1.15AURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/ACRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.6611.896.743.8811.00%15.12%7.14%8/6/2026 (Estimated)AURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%8/12/2026 (Estimated)CRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)Latest CRDL, ORPH, AMPH, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 million3/30/2026Q4 2025AURAAura Biosciences-$0.43-$0.37+$0.06-$0.37N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82AURAAura BiosciencesN/A7.097.09CRDLCardiol TherapeuticsN/A4.394.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%AURAAura Biosciences96.75%CRDLCardiol Therapeutics12.49%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%AURAAura Biosciences6.30%CRDLCardiol Therapeutics5.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableAURAAura Biosciences50103.39 million96.87 millionNot OptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableCRDL, ORPH, AMPH, and AURA HeadlinesRecent News About These CompaniesCritical Review: UCB (OTCMKTS:UCBJY) versus Cardiol Therapeutics (NASDAQ:CRDL)May 30, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)May 20, 2026 | theglobeandmail.comCardiol Therapeutics to Present Pipeline at H.C. Wainwright BioConnect Conference at NASDAQMay 14, 2026 | tipranks.comCardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQMay 14, 2026 | prnewswire.comCardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart AssociationMay 7, 2026 | prnewswire.comCardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal ProgramApril 28, 2026 | prnewswire.comCardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartApril 14, 2026 | finanznachrichten.deCardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live InterviewApril 14, 2026 | tipranks.comCardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartApril 14, 2026 | newsfilecorp.comNCardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of ShareholdersApril 10, 2026 | tipranks.comCardiol Therapeutics Announces Year-End 2025 Update on OperationsApril 1, 2026 | newsfilecorp.comNWhy Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 7.22%March 30, 2026 | aaii.comACardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care ConferenceFebruary 25, 2026 | tipranks.comCardiol Therapeutics to Present at TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | newsfilecorp.comNCardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart FailureFebruary 10, 2026 | tipranks.comCardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart FailureFebruary 10, 2026 | newsfilecorp.comNCardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 MillionJanuary 23, 2026 | newsfilecorp.comNTop Canadian Stocks to Buy Right Away With $5,000January 21, 2026 | msn.comCardiol Therapeutics Inc.: Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 MillionJanuary 16, 2026 | finanznachrichten.deCardiol Therapeutics announces $13.5M bought-deal private placementJanuary 16, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyBy Chris Markoch | May 23, 2026CRDL, ORPH, AMPH, and AURA Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$19.74 +1.04 (+5.56%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$19.86 +0.13 (+0.63%) As of 06/5/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Aura Biosciences NASDAQ:AURA$6.63 -0.17 (-2.50%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$6.62 0.00 (-0.08%) As of 06/5/2026 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Cardiol Therapeutics NASDAQ:CRDL$1.11 -0.04 (-3.48%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.12 +0.01 (+0.90%) As of 06/5/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
